ABL1 and acute lymphoblastic leukemia: Notably, although TCF3::PBX1 B-ALL patients are generally considered low risk39, all four TCF3::PBX1 cases in this analysis were grouped with the KMT2A and BCR::ABL1\BCR::ABL1-like cases in Group B and relapsed within 22 months from diagnosis (Fig. 5b).